Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Apalutamide benefit sustained in mCSPC regardless of next therapy

Key clinical point: Adding apalutamide to ADT in mCSPC prolongs time to second progression or death regardless of subsequent therapy.

Major finding: Time to second progression or death was better with initial apalutamide vs. placebo whether patients later received a new hormonal therapy (hazard ratio, 0.684; P = .0326) or taxane chemotherapy (hazard ratio, 0.634; P = .0062).

Study details: A post hoc analysis of 277 men from a phase 3 randomized controlled trial of apalutamide vs. placebo, each added to ADT, for metastatic castration-sensitive prostate cancer (TITAN trial).

Disclosures: The trial was funded by Janssen Research & Development. Dr. Agarwal and Dr. Rathkopf each disclosed a consulting or advisory role or research funding (all institutional) with numerous pharmaceutical companies, including Janssen.


Agarwal N et al. GUCS 2020. Abstract 82.